These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. Dickerson BC; Sperling RA NeuroRx; 2005 Apr; 2(2):348-60. PubMed ID: 15897955 [TBL] [Abstract][Full Text] [Related]
28. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097 [TBL] [Abstract][Full Text] [Related]
29. EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. Gaubert S; Raimondo F; Houot M; Corsi MC; Naccache L; Diego Sitt J; Hermann B; Oudiette D; Gagliardi G; Habert MO; Dubois B; De Vico Fallani F; Bakardjian H; Epelbaum S; Brain; 2019 Jul; 142(7):2096-2112. PubMed ID: 31211359 [TBL] [Abstract][Full Text] [Related]
30. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial. Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786 [TBL] [Abstract][Full Text] [Related]
33. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Vos SJB; Gordon BA; Su Y; Visser PJ; Holtzman DM; Morris JC; Fagan AM; Benzinger TLS Neurobiol Aging; 2016 Aug; 44():1-8. PubMed ID: 27318129 [TBL] [Abstract][Full Text] [Related]
34. Subthreshold Amyloid Predicts Tau Deposition in Aging. Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045 [TBL] [Abstract][Full Text] [Related]
35. The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials. Olsson B; Schott JM; Blennow K; Zetterberg H Expert Rev Neurother; 2017 Aug; 17(8):767-775. PubMed ID: 28604243 [TBL] [Abstract][Full Text] [Related]
36. Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective. Hampel H; Prvulovic D J Nutr Health Aging; 2012 Apr; 16(4):346-8. PubMed ID: 22499455 [TBL] [Abstract][Full Text] [Related]
37. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Klunk WE Neurobiol Aging; 2011 Dec; 32 Suppl 1(Suppl 1):S20-36. PubMed ID: 22078170 [TBL] [Abstract][Full Text] [Related]
38. Feasibility and acceptance of simultaneous amyloid PET/MRI. Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367 [TBL] [Abstract][Full Text] [Related]
39. The dynamic marker hypothesis of Alzheimer's disease and its implications for clinical imaging. Cavedo E; Frisoni GB Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):237-49. PubMed ID: 21532538 [TBL] [Abstract][Full Text] [Related]
40. Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia. Fink HA; Linskens EJ; Silverman PC; McCarten JR; Hemmy LS; Ouellette JM; Greer NL; Wilt TJ; Butler M Ann Intern Med; 2020 May; 172(10):669-677. PubMed ID: 32340038 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]